NASDAQ:INNT Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis → Everything from semiconductors to space shuttles depend on this overlooked mineral (From Capital Trends) (Ad) Free INNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.56▼$1.4252-Week Range N/AVolume18 shsAverage Volume525,982 shsMarket Capitalization$8,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesTrendsStock AnalysisCompetitorsHeadlinesTrends Get Innovate Biopharmaceuticals alerts: Email Address Ad Capital TrendsOverlooked Mineral Essential To Quantum Computing and AIBoron is also at the heart of a breakthrough that could fuel one of mankind's most sensational advances in semiconductor technologies. A critical next step to satisfy the massive processing needs of AI and quantum computing.Click here to learn how this overlooked mineral shapes the world today About Innovate Biopharmaceuticals Stock (NASDAQ:INNT)Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Read More Ad Capital TrendsOverlooked Mineral Essential To Quantum Computing and AIBoron is also at the heart of a breakthrough that could fuel one of mankind's most sensational advances in semiconductor technologies. A critical next step to satisfy the massive processing needs of AI and quantum computing.Click here to learn how this overlooked mineral shapes the world today INNT Stock News HeadlinesMay 28, 2024 | finanznachrichten.deTurn Biotechnologies, Inc.: Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear TherapiesMay 24, 2024 | finanznachrichten.deFSD Pharma Inc.: FSD Pharma Provides Corporate UpdateMay 22, 2024 | tmcnet.com"EMBRACING INTERNATIONAL ALLIANCES" SWISS BIOTECH INNOVATION ON DISPLAY AT THE BIO 2024 INTERNATIONAL CONVENTION IN SAN DIEGO JUNE 3-6, 2024May 21, 2024 | finance.yahoo.comBiopharmaceuticals Contract Manufacturing Global Market Report 2024May 15, 2024 | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialMay 15, 2024 | ca.finance.yahoo.comCybin Inc. (CYBN)May 14, 2024 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings UpdateMay 10, 2024 | benzinga.comLirum Therapeutics, Inc IPOs Tomorrow, Here's What You Need To KnowMay 7, 2024 | markets.businessinsider.comNuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business HighlightsMay 6, 2024 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global ConferenceMay 3, 2024 | finanznachrichten.deArdelyx, Inc.: Ardelyx Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 3, 2024 | uk.finance.yahoo.comDecoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT InsightMay 3, 2024 | finanznachrichten.deWerewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)May 1, 2024 | markets.businessinsider.comStrategic Advisory for Leading Therapeutics Innovation Inc. (SALTI) Launches as New Management Consulting FirmApril 30, 2024 | tmcnet.comCaris Life Sciences and COTA, Inc. Announce Collaboration to Expand Collective Multi-Modal Data OfferingApril 30, 2024 | msn.comOcugen to Present Pioneering Gene Therapy Data at Retinal Innovation SummitApril 30, 2024 | finance.yahoo.comReflect Scientific Inc Secures $550,000 Sale with Major BioPharma CompanyApril 27, 2024 | bizjournals.comAll about preservation — Innovation Campus Phase 1April 26, 2024 | finance.yahoo.comRakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate UpdateApril 23, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the LSX World Congress 2024April 22, 2024 | finance.yahoo.comSystImmune, Inc. Appoints Dr. Jie D'Elia as Chief Executive OfficerApril 19, 2024 | msn.comInnovate Change - best online casinos review by the experts 2024April 18, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic RetinopathyApril 15, 2024 | finance.yahoo.comThird Harmonic Bio Inc CEO Natalie Holles Sells 13,558 SharesSee More Headlines Receive INNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2019Today6/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:INNT CUSIPN/A CIK1551986 Webwww.innovatebiopharma.com Phone919-275-1933FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,050,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-234.42% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / BookN/AMiscellaneous Outstanding Shares41,325,000Free FloatN/AMarket Cap$8,000.00 OptionableNot Optionable Beta-0.39 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Sandeep Laumas M.D. (Age 50)CEO & Exec. Chairman Mr. Jay P. Madan M.S. (Age 53)Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director Dr. Christopher P. Prior (Age 66)Consultant Jerry Gardner M.D.Head of Clinical StrategyDr. Patrick H. Griffin (Age 64)Chief Medical Officer Key CompetitorsNVN LiquidationNASDAQ:NOVNQEvelo BiosciencesNASDAQ:EVLOScopus BioPharmaNASDAQ:SCPSOncoSec MedicalNASDAQ:ONCSQGrifolsNASDAQ:GRFSView All Competitors INNT Stock Analysis - Frequently Asked Questions How were Innovate Biopharmaceuticals' earnings last quarter? Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). What other stocks do shareholders of Innovate Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Micron Technology (MU), Nabriva Therapeutics (NBRV), Neurotrope (NTRP) and This page (NASDAQ:INNT) was last updated on 6/5/2024 by MarketBeat.com Staff From Our PartnersUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes| SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredEverything from semiconductors to space shuttles depend on this overlooked mineralBoron is also at the heart of a breakthrough that could fuel one of mankind's most sensational advances in sem...Capital Trends| SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press| SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovate Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.